Biotech Values

[DewDiligence]

How do these [Laquinimod] rates compare to Copaxone?

There have been many Copaxone studies, so I’ll confine the answer to the two studies cited in the FDA label that measured the relapse rate and the rate of disability progression based on the DSS scale.

http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=COPAXONE

In these studies, Copaxone showed a 75% and 29% reduction, respectively, in the relapse rate (n=50 and n=251, respectively, randomized 1:1 Copaxone:placebo). The blended reduction in relapse rate in these two studies combined was 39%.

There was no statsig reduction in the rate of disability progression based on the DSS scale in either study, although the smaller study came close (p=0.07) and the larger study showed a statsig benefit in the mean change in DSS score relative to baseline.